1. Natoli J, Boer R, Nathanson B, Miller R, Chiroli S, Goodman W, Belozeroff V. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease?. BMC Nephrol. 2013; 17:14–88.
2. Tentori F, Blayney M, Albert J, Gillespie B, Kerr P, Bommer J, Young E, Akizawa T, Akiba T, Pisoni R, Robinson B, Port F. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and pth: the dialysis outcomes and practice patterns study (dopps). Am J Kidney Dis. 2008; 52(3):519–30.
3. Copland M, Komenda P, Weinhandl E, McCullough P, Morfin J. Intensive hemodialysis, mineral and bone disorder, and phosphate binder use. Am J Kidney Dis. 2016; 68(5S1):24–32.
4. KDIGO. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (ckd-mbd). Kidney Int Suppl. 2017; 7(1):1–56.
5. Minutolo R, Bellizzi V, Cioffi M, Iodice C, Giannattasio P, Andreucci M, Terracciano V, Di Iorio B, Conte G, Nicola LD. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol. 2002; 13:1046–54.